Deucravacitinib: A Year in Review
As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.
New Drugs in 2023, Patient Satisfaction, and RAD Takeaways With Melinda Gooderham, MSc, MD, FRCPC
Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.
